Several clinically used drugs have demonstrated significant anti-CRC effects by targeting YAP, Metformin, a widely used drug for type 2 diabetes, inhibits YAP nuclear function by promoting its phosphorylation, thereby reducing CRC cells’ immune evasion (115). The gene discussed is YAP1; the disease is type 2 diabetes mellitus.